AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02272725
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen
Trial: NCT02272725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasteless and inert visually identical (to ibuprofen) pills
Trial: NCT00185692
Drug: Solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
Trial: NCT00185692
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg PO, 30 minutes prior to infusion Pain reliever
Trial: NCT00185692
Drug: Diphenydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
Trial: NCT00185692
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
Trial: NCT01470209
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
Trial: NCT01313143
Drug: AOP200704
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of AOP200704 with Esmolol
Trial: NCT03925233
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin Hydrochloride Injection
Trial: NCT03925233
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil injection
Trial: NCT03925233
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate injection
Trial: NCT03925233
Drug: Pattozumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pattozumab injection
Trial: NCT03925233
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine tablets
Trial: NCT03925233
Drug: Ear particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear particles
Trial: NCT03925233
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide injection
Trial: NCT00045708
Drug: Anticonvulsant
RxNorm normalized name: Anticonvulsant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs that induce hepatic Metabolic enzymes
Trial: NCT03884517
Drug: BAT8003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Trial: NCT03173742
Drug: T1, T2, T3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Trial: NCT03173742
Drug: T1,T3,T2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Trial: NCT03173742
Drug: T2,T1,T3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Trial: NCT03173742
Drug: T2,T3,T1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Trial: NCT03173742
Drug: T3,T1,T2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Trial: NCT03173742
Drug: T3,T2,T1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Trial: NCT01040195
Drug: Methotrexate, Hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
Trial: NCT01040195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
Trial: NCT02357004
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg daily in addition to normal BP medications
Trial: NCT04128293
Drug: GSK3640254 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Trial: NCT01595867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (100 mg) placebo tablets crushed; single dose
Trial: NCT04724343
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage adjustment according to the ovarian response.
Trial: NCT01940900
Drug: E10030
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01063270
Drug: Clindamycin & Rifampin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
Trial: NCT00342381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose placebo treatment
Trial: NCT03852628
Drug: Placebo (SL pill qd, IM injection q4weeks)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
Trial: NCT00464516
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 14 days orally
Trial: NCT03065959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03391765
Drug: Placebo solution for IV infusion on Day 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
Trial: NCT03115294
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv injection
Trial: NCT03896009
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam taken once upon onset of a qualifying migraine.
Trial: NCT03896009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken once upon onset of a qualifying migraine.
Trial: NCT04210388
Drug: AZD5718 tablet, Formulation A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Trial: NCT04210388
Drug: AZD5718 tablet, Formulation B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Trial: NCT04210388
Drug: AZD5718 tablet, Formulation C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Trial: NCT04210388
Drug: AZD5718 tablet, Formulation D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Trial: NCT01005914
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
Trial: NCT01005914
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 4: 50 mg/m2 IV over 2 hours
Trial: NCT01005914
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
Trial: NCT04210388
Drug: AZD5718 film-coated tablet, Reference treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Trial: NCT04257032
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT04257032
Drug: Rosuvastatin + BI 1323495
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00186966
Drug: Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description section for details of treatment interventions.
Trial: NCT02695004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02113150
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: renal function
Trial: NCT02770404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV matching placebo
Trial: NCT02262689
Drug: GSK2256294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
Trial: NCT02262689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo will be supplied as gelatin capsule to be administered orally
Trial: NCT00437645
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT00404547
Drug: Usual Care Inhaled Glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
Trial: NCT02655016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT02957435
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
Trial: NCT00041977
Drug: doxycycline hyclate 20 mg twice daily
RxNorm normalized name: doxycycline hyclate 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01061333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
Trial: NCT00003578
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003578
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003084
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV on days 1, 15, and 29.
Trial: NCT02289547
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maintenance capecitabine therapy after six cycles of XELOX
Trial: NCT00327002
Drug: LY518674
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00688701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT04645901
Drug: Drug: SYHA1805 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of SYHA1805 with several doses
Trial: NCT04645901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of placebo with matching several doses
Trial: NCT04589546
Drug: Nicotinamide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
Trial: NCT04589546
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
Trial: NCT02222363
Drug: VLX600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
Trial: NCT00251303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules matched active drug in appearance.
Trial: NCT00026442
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05386667
Drug: Majezik %0.25 oral spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day.
Trial: NCT02988440
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 will be administered intravenously
Trial: NCT00453531
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02280031
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule containing Acetylsalicylic Acid 80mg pill with lactose
Trial: NCT03609099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day oral treatment during 3 days.
Trial: NCT02047994
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days
Trial: NCT01373931
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01373931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01583959
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid tablets 5 mg
Trial: NCT02572596
Drug: CTX
RxNorm normalized name: CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTX 2.5/m2 for 2 days.
Trial: NCT01583959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
Trial: NCT00811785
Drug: Copper Histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections for three years
Trial: NCT00985725
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily
Trial: NCT00504725
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03895411
Drug: betaloc
RxNorm normalized name: Betaloc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral betaloc 0.5mg/kg/time ,pre 12h
Trial: NCT03320018
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period.
Trial: NCT00659490
Drug: AZD1940
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800ug oral administration
Trial: NCT00659490
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg oral administration
Trial: NCT00659490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given pre-surgery
Trial: NCT00827541
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Trial: NCT00801281
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
Trial: NCT00801281
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
Trial: NCT02706886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
Trial: NCT01264237
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90mg Tablet QD at 10:00a.m.
Trial: NCT01264237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet QD at 10:00a.m.
Trial: NCT02274454
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
Trial: NCT03716375
Drug: Intrapleural Medications
RxNorm normalized name: INTRAPLEURAL MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urokinase
Trial: NCT00336791
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle.
Trial: NCT00336791
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
Trial: NCT02849860
Drug: IDP-121 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion